Nail Renewal Liquid

Dosage for Sophora Flavescens Root varies significantly based on the indication and the specific formulation used. Because this is a non-standardized extract, patients must adhere strictly to the manufacturer's label or their physician's instructions.

• For General Inflammatory Conditions (Oral): Typical dosages of standardized matrine extracts range from 200 mg to 600 mg daily, divided into two or three doses. If using the raw dried root (Ku Shen), traditional decoctions often utilize 3 to 10 grams of the root boiled in water.
• For Topical Antifungal Use: Apply a 2-5% concentration gel or ointment to the affected area twice daily (morning and evening) for 2 to 4 weeks. Treatment should continue for at least one week after symptoms disappear to prevent recurrence.
• For Allergenic Testing: Dosage is determined by the allergist, usually involving a single drop of a 1:10 or 1:20 w/v (weight/volume) extract applied during a skin prick test.

Sophora Flavescens Root is generally not recommended for pediatric use unless specifically directed by a specialist. There is a lack of robust clinical data regarding the safety and efficacy of matrine and oxymatrine in children. In cases where it is used (e.g., for specific dermatological conditions), dosages must be strictly weight-based and monitored by a pediatrician to avoid potential neurotoxicity.

Renal Impairment

Since the primary route of elimination for matrine is renal, patients with a Glomerular Filtration Rate (GFR) below 60 mL/min may require a dose reduction of 25-50%. In patients with end-stage renal disease (ESRD), use is generally avoided due to the risk of accumulation and toxicity.

Hepatic Impairment

Although it is used to treat certain liver conditions, Sophora Flavescens Root undergoes extensive hepatic metabolism. Patients with Child-Pugh Class B or C hepatic impairment should use this medication with extreme caution. Liver function tests (LFTs) should be monitored bi-weekly during the initiation of therapy.

Elderly Patients

Geriatric patients often have reduced renal and hepatic reserve. Dosing should start at the lowest end of the therapeutic range. There is an increased risk of dizziness and falls in this population when taking systemic Sophora extracts.

• Oral Administration: Capsules or tablets should be taken with a full glass of water. It is generally recommended to take the medication with food to minimize gastrointestinal irritation.
• Topical Administration: Clean and dry the affected area before application. Do not cover the area with an occlusive dressing (such as plastic wrap) unless directed by your doctor, as this may increase systemic absorption and the risk of side effects.
• Storage: Store all forms at room temperature (68°F to 77°F or 20°C to 25°C), away from direct sunlight and moisture. Keep out of reach of children.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up, as this increases the risk of alkaloid toxicity.

Signs of a Sophora Flavescens Root overdose (specifically matrine toxicity) include:

• Severe dizziness or vertigo
• Muscle tremors or twitching
• Nausea and projectile vomiting
• Shortness of breath (dyspnea)
• Convulsions or seizures (in extreme cases)

In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on airway management and seizure control.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication without medical guidance, as this may lead to treatment failure or withdrawal-like symptoms in chronic users.

Systemic administration of Sophora Flavescens Root extracts most commonly affects the gastrointestinal and central nervous systems. Many patients report the following:

• Gastrointestinal Distress: This includes nausea, a feeling of fullness, and mild stomach cramps. These symptoms typically occur within the first hour of oral dosing and may diminish as the body adjusts to the medication.
• Dizziness: A transient sensation of lightheadedness or vertigo is frequently reported, likely due to the alkaloids' ability to cross the blood-brain barrier.
• Dry Mouth (Xerostomia): Patients may experience a persistent dry sensation in the mouth and throat.

• Constipation or Diarrhea: Alterations in bowel habits may occur depending on the individual's sensitivity to the root's tannins and alkaloids.
• Headache: Mild to moderate tension-type headaches have been noted in clinical trials.
• Insomnia: Some patients report difficulty falling asleep if the medication is taken late in the evening, suggesting a mild stimulatory effect on the nervous system in some individuals.
• Skin Rash (Topical): When applied to the skin, mild redness, itching, or a burning sensation may occur at the site of application.

• Hepatotoxicity: Paradoxically, while used for liver support, high doses or prolonged use have been linked to drug-induced liver injury (DILI). Symptoms include yellowing of the skin or eyes (jaundice) and dark urine.
• Leukopenia: A reduction in white blood cell count has been observed in rare cases, potentially increasing the risk of infection.
• Cardiac Arrhythmias: Although rare, some individuals may experience palpitations or an irregular heartbeat due to the alkaloids' influence on cardiac ion channels.

> Warning: Stop taking Sophora Flavescens Root and call your doctor immediately if you experience any of these serious symptoms.

• Anaphylaxis: Signs include hives, swelling of the face, lips, or tongue, and severe difficulty breathing. This is a critical risk given its classification as an allergenic extract.
• Seizures: Matrine has a known neurotoxic threshold. Any signs of involuntary muscle contractions or loss of consciousness require emergency intervention.
• Severe Hepatotoxicity: If you experience persistent upper right abdominal pain, extreme fatigue, or clay-colored stools, seek medical help immediately.
• Visual Disturbances: Blurred vision or temporary loss of peripheral vision may indicate central nervous system toxicity.

Prolonged use of Sophora Flavescens Root (exceeding 3 months) may lead to:

• Tolerance: The anti-inflammatory effects may diminish over time, requiring higher doses which increases toxicity risk.
• Cumulative Neurotoxicity: Small, daily doses of matrine may accumulate in the central nervous system, leading to chronic tremors or cognitive clouding.
• Kidney Strain: Chronic excretion of alkaloids can lead to mild elevations in serum creatinine levels.

No FDA black box warnings currently exist for Sophora Flavescens Root. However, the FDA mandates that all Non-Standardized Plant Allergenic Extracts carry warnings regarding the risk of severe systemic allergic reactions (anaphylaxis) during diagnostic testing or treatment. Healthcare providers must be prepared to treat anaphylaxis with epinephrine whenever these extracts are administered in a clinical setting.

Report any unusual symptoms or persistent side effects to your healthcare provider. Monitoring of blood counts and liver enzymes is recommended for anyone using this substance for more than four consecutive weeks.

Sophora Flavescens Root contains potent alkaloids that behave like pharmaceutical drugs. It is not a "mild" herbal supplement and should be treated with the same caution as synthetic medications. Patients must be aware that the concentration of active ingredients can vary widely between different brands and batches of the root extract.

No FDA black box warnings for Sophora Flavescens Root. However, clinicians are cautioned that as a Non-Standardized Plant Allergenic Extract, there is a significant risk of inducing a systemic allergic reaction during skin testing. This procedure should only be performed in facilities equipped with emergency resuscitation equipment.

• Allergic Reactions / Anaphylaxis Risk: Because this drug is used as an allergenic extract, patients with a history of severe asthma or multiple environmental allergies are at a higher risk for cross-reactivity. Anaphylaxis can occur even with topical application if the skin barrier is compromised.
• Neurotoxicity: The alkaloid matrine is a central nervous system (CNS) active compound. It can lower the seizure threshold. Patients with pre-existing epilepsy or those taking other medications that lower the seizure threshold (such as bupropion or tramadol) must use Sophora with extreme caution.
• Hepatotoxicity: While used in some cultures to treat hepatitis, there is evidence that high doses can cause liver damage. Baseline liver function tests (LFTs) are recommended before starting systemic therapy.
• QT Prolongation: There is emerging evidence that certain constituents of Sophora Flavescens Root may affect the electrical activity of the heart. Patients with a history of long QT syndrome or those taking other QT-prolonging drugs should be monitored via ECG.

If you are taking Sophora Flavescens Root systemically for more than 14 days, your healthcare provider may require the following tests:

• Complete Blood Count (CBC): To monitor for leukopenia or other blood dyscrasias.
• Liver Function Tests (ALT, AST, Bilirubin): To ensure the liver is processing the alkaloids safely.
• Renal Function Tests (BUN, Creatinine): To monitor clearance, especially in older adults.

Sophora Flavescens Root frequently causes dizziness and may cause blurred vision or mild cognitive impairment. Do not drive or operate heavy machinery until you know how this medication affects you. These effects are often most pronounced during the first week of treatment or after a dose increase.

Alcohol should be avoided while taking Sophora Flavescens Root. Alcohol can exacerbate the dizziness and GI upset caused by the root and may increase the risk of hepatotoxicity. Furthermore, since Sophora inhibits CYP3A4, it may alter the metabolism of alcohol-related medications.

Do not stop taking systemic Sophora Flavescens Root abruptly if you have been using it for a long period. While it is not traditionally associated with a withdrawal syndrome, a sudden cessation can lead to a "rebound" of inflammatory symptoms. A gradual taper over 7-10 days is often recommended by healthcare providers.

> Important: Discuss all your medical conditions, especially any history of seizures, liver disease, or heart rhythm problems, with your healthcare provider before starting Sophora Flavescens Root.

Sophora Flavescens Root should never be used with the following medications due to the risk of life-threatening interactions:

• Terfenadine and Astemizole: Although largely withdrawn from many markets, these antihistamines, when combined with a CYP3A4 inhibitor like Sophora, can lead to fatal cardiac arrhythmias (Torsades de Pointes).
• Cisapride: Inhibition of its metabolism by Sophora can cause dangerous QT prolongation.
• Ergot Alkaloids (e.g., Ergotamine): Sophora may increase serum levels of these drugs, leading to ergotism (severe vasoconstriction and gangrene).

• Immunosuppressants (Cyclosporine, Tacrolimus): Sophora inhibits P-Glycoprotein (P-gp) and CYP3A4, which are the primary pathways for these drugs. This can lead to toxic levels of immunosuppressants, resulting in kidney failure.
• Warfarin: Sophora may enhance the anticoagulant effect of Warfarin, increasing the risk of major bleeding. Frequent INR monitoring is mandatory.
• Statins (Atorvastatin, Simvastatin): These are major CYP3A4 substrates. Using them with Sophora increases the risk of myopathy and rhabdomyolysis (muscle breakdown).

• Calcium Channel Blockers (Amlodipine, Diltiazem): Sophora can increase the concentration of these drugs, leading to excessively low blood pressure (hypotension) and a slow heart rate (bradycardia).
• Benzodiazepines (Alprazolam, Midazolam): Expect increased sedation and respiratory depression as Sophora slows the clearance of these medications.
• Digoxin: As a P-gp inhibitor, Sophora can increase the absorption and decrease the excretion of Digoxin, potentially leading to digitalis toxicity (nausea, halos in vision, arrhythmias).

• Grapefruit and Grapefruit Juice: Both Sophora and grapefruit are potent CYP3A4 inhibitors. Combining them can lead to unpredictable and dangerously high levels of other medications you may be taking.
• High-Fat Meals: May delay the absorption of matrine, potentially reducing the efficacy of the drug for acute symptoms but increasing the risk of late-onset side effects.

• St. John's Wort: This herb is a CYP3A4 inducer, which is the opposite of Sophora. Taking them together will create unpredictable drug levels and likely negate the benefits of Sophora.
• Kava and Valerian: These may increase the CNS-depressant effects (dizziness, sedation) of Sophora Flavescens Root.
• Hepatotoxic Herbs (Comfrey, Chaparral): Avoid combining Sophora with other herbs known to stress the liver.

• Liver Function Tests: Sophora can cause false elevations in ALT and AST levels.
• Urine Glucose Tests: Some alkaloids in the root may interfere with copper reduction tests for glucose in the urine, leading to false-positive results.

For each major interaction, the mechanism typically involves the competitive inhibition of the CYP3A4 enzyme or the blockade of the P-gp efflux pump. This results in higher systemic exposure to the co-administered drug, potentially leading to toxicity. Management usually involves dose reduction of the substrate drug or choosing an alternative medication that is not metabolized by the CYP3A4 pathway.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs and vitamins.

Sophora Flavescens Root must NEVER be used in the following circumstances:

• Hypersensitivity: Any known allergy to Sophora flavescens, matrine, oxymatrine, or other members of the Fabaceae (legume) family. The risk of anaphylaxis is high in these individuals.
• Pregnancy: Due to documented teratogenic effects (birth defects) in animal studies and the ability of matrine to cross the placental barrier, it is strictly contraindicated.
• Severe Hepatic Failure: Patients with decompensated cirrhosis or acute liver failure cannot safely metabolize the alkaloids.
• Active Seizure Disorders: Because the extract can lower the seizure threshold, it is contraindicated in patients with uncontrolled epilepsy.

Conditions requiring a careful risk-benefit analysis by a physician include:

• Moderate Renal Impairment: Requires significant dose adjustments and close monitoring of serum creatinine.
• Cardiac Conduction Abnormalities: Patients with pre-existing bradycardia or first-degree heart block should be monitored for worsening of these conditions.
• Gastrointestinal Ulcers: The tannins and alkaloids may irritate the gastric mucosa, potentially worsening active peptic ulcer disease.
• Breastfeeding: While not an absolute contraindication in all regions, the lack of safety data and the potential for infant neurotoxicity make it a relative contraindication.

Patients who are allergic to other legumes—such as soy, peanuts, chickpeas, or lentils—may exhibit cross-sensitivity to Sophora Flavescens Root. If you have a severe allergy to any of these foods, inform your allergist before undergoing testing with Sophora extracts. Additionally, those sensitive to other Sophora species (like Sophora japonica) should avoid this root extract.

> Important: Your healthcare provider will evaluate your complete medical history, including all allergies and chronic conditions, before prescribing or administering Sophora Flavescens Root.

Sophora Flavescens Root is classified as Category X in some jurisdictions and should be considered highly dangerous during pregnancy. Research in animal models has shown that matrine and oxymatrine can cause structural malformations, particularly in the skeletal and nervous systems of the fetus. Furthermore, these alkaloids can induce uterine contractions, which may lead to miscarriage or preterm labor. If you become pregnant while taking this medication, stop use immediately and contact your obstetrician.

It is unknown if the components of Sophora Flavescens Root are excreted in human milk in significant quantities. However, because matrine is a small, lipophilic molecule, it is highly likely to pass into breast milk. Given the potential for neurotoxicity and the immature metabolic pathways of a nursing infant, breastfeeding is not recommended while using systemic Sophora extracts. Topical use on small areas of the skin (away from the breast) may be considered only if the benefit clearly outweighs the risk.

Sophora Flavescens Root is not approved for use in children under the age of 12. In adolescents (12-18 years), it should be used with extreme caution. Children are more susceptible to the CNS-depressant and neurotoxic effects of matrine. There are no established safe dosing guidelines for the pediatric population, and use in this group is generally considered off-label and high-risk.

Patients over the age of 65 are at a significantly higher risk for adverse reactions. Age-related declines in GFR mean that the drug remains in the system longer, increasing the risk of cumulative toxicity. Elderly patients are also more likely to be on multiple medications (polypharmacy), making the CYP3A4 and P-gp inhibitory effects of Sophora particularly dangerous. Falls resulting from dizziness are a major concern in this population.

In patients with renal impairment, the clearance of matrine is significantly reduced.

• Mild Impairment (CrCl 60-89 mL/min): No initial adjustment needed, but monitor closely.
• Moderate Impairment (CrCl 30-59 mL/min): Reduce dose by 50%.
• Severe Impairment (CrCl <30 mL/min): Use is not recommended.

Sophora is not known to be effectively cleared by hemodialysis.

For patients with hepatic impairment, the risk of drug-induced liver injury (DILI) is elevated. In patients with Child-Pugh Class A, use with caution. For Child-Pugh Class B and C, the drug is generally avoided. If use is deemed necessary, liver enzymes must be checked weekly during the first month of therapy.

> Important: Special populations require individualized medical assessment. Never share this medication with others, especially those in these high-risk groups.

Sophora Flavescens Root exerts its effects through several distinct molecular pathways. The primary alkaloids, matrine and oxymatrine, act as agonists at certain opioid receptors (kappa and mu), which contributes to their analgesic and sedative properties. More importantly, they inhibit the IKK/NF-κB signaling pathway, which prevents the translocation of NF-κB into the nucleus, thereby halting the transcription of pro-inflammatory genes.

As an Azole Antifungal [EPC], it inhibits the enzyme lanosterol 14α-demethylase. This enzyme is essential for converting lanosterol into ergosterol. The resulting depletion of ergosterol and the accumulation of toxic methylated sterols lead to the disruption of the fungal cell membrane, resulting in cell death (fungicidal) or inhibited growth (fungistatic).

The anti-inflammatory effect of Sophora Flavescens Root is dose-dependent. Onset of action for topical antifungal effects is usually seen within 48 to 72 hours, while systemic anti-inflammatory effects may take 5 to 7 days of consistent dosing to become apparent. Tolerance to the sedative effects may develop with chronic use, but the anti-inflammatory and antifungal properties generally remain stable.

| Parameter | Value |

|---|---|

| Bioavailability | 18% - 44% (Oral Matrine) |

| Protein Binding | 30% - 40% |

| Half-life | 3 - 6 hours |

| Tmax | 1 - 2 hours |

| Metabolism | Hepatic (CYP3A4, CYP3A5, CYP1A2) |

| Excretion | Renal (50-60% unchanged) |

• Molecular Formula (Matrine): C15H24N2O
• Molecular Weight: 248.36 g/mol
• Solubility: Soluble in water, benzene, and chloroform; moderately soluble in petroleum ether.
• Structure: A quinolizidine alkaloid consisting of four fused rings. It is the primary bioactive marker used for the standardization of Sophora extracts.

Sophora Flavescens Root is categorized as a Non-Standardized Plant Allergenic Extract [EPC] and an Azole Antifungal [EPC]. It is related to other quinolizidine alkaloid-containing plants but is unique in its high concentration of matrine. In terms of its antifungal activity, it is pharmacologically grouped with synthetic azoles like Clotrimazole and Ketoconazole, despite its botanical origin.